Is Innate Pharma Stock a Good Investment?
Innate Pharma Investment Advice | IPHA |
- Examine Innate Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Innate Pharma's leadership team and their track record. Good management can help Innate Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Innate Pharma's business and its evolving consumer preferences.
- Compare Innate Pharma's performance and market position to its competitors. Analyze how Innate Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Innate Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Innate Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Innate Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Innate Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Innate Pharma Stock
Researching Innate Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.44. Innate Pharma had not issued any dividends in recent years.
To determine if Innate Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Innate Pharma's research are outlined below:
| Innate Pharma is way too risky over 90 days horizon | |
| Innate Pharma appears to be risky and price may revert if volatility continues | |
| Innate Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 51.9 M. Net Loss for the year was (7.57 M) with loss before overhead, payroll, taxes, and interest of (19.86 M). | |
| Innate Pharma currently holds about 123.35 M in cash with (32.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54. |
Innate Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Innate Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Innate Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Innate Pharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 192.27 M.Innate Pharma's profitablity analysis
The company has Profit Margin (PM) of (1.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.13.Determining Innate Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Innate Pharma is a good buy. For example, gross profit margin measures Innate Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Innate Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Innate Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innate Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innate Pharma's management manipulating its earnings.
Basic technical analysis of Innate Stock
As of the 27th of February, Innate Pharma retains the Market Risk Adjusted Performance of 1.36, risk adjusted performance of 0.08, and Downside Deviation of 6.93. Innate Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Innate Pharma's Outstanding Corporate Bonds
Innate Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Innate Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Innate bonds can be classified according to their maturity, which is the date when Innate Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45782BAD64 Corp BondUS45782BAD64 | View | |
| Installed Building Products Corp BondUS45780RAA95 | View |
Understand Innate Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Innate Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.08 | |||
| Market Risk Adjusted Performance | 1.36 | |||
| Mean Deviation | 6.28 | |||
| Semi Deviation | 5.5 | |||
| Downside Deviation | 6.93 | |||
| Coefficient Of Variation | 1043.14 | |||
| Standard Deviation | 14.29 | |||
| Variance | 204.34 | |||
| Information Ratio | 0.0956 | |||
| Jensen Alpha | 1.37 | |||
| Total Risk Alpha | 1.49 | |||
| Sortino Ratio | 0.1971 | |||
| Treynor Ratio | 1.35 | |||
| Maximum Drawdown | 116.36 | |||
| Value At Risk | (9.28) | |||
| Potential Upside | 20.62 | |||
| Downside Variance | 48.07 | |||
| Semi Variance | 30.3 | |||
| Expected Short fall | (8.99) | |||
| Skewness | 5.05 | |||
| Kurtosis | 32.32 |
| Risk Adjusted Performance | 0.08 | |||
| Market Risk Adjusted Performance | 1.36 | |||
| Mean Deviation | 6.28 | |||
| Semi Deviation | 5.5 | |||
| Downside Deviation | 6.93 | |||
| Coefficient Of Variation | 1043.14 | |||
| Standard Deviation | 14.29 | |||
| Variance | 204.34 | |||
| Information Ratio | 0.0956 | |||
| Jensen Alpha | 1.37 | |||
| Total Risk Alpha | 1.49 | |||
| Sortino Ratio | 0.1971 | |||
| Treynor Ratio | 1.35 | |||
| Maximum Drawdown | 116.36 | |||
| Value At Risk | (9.28) | |||
| Potential Upside | 20.62 | |||
| Downside Variance | 48.07 | |||
| Semi Variance | 30.3 | |||
| Expected Short fall | (8.99) | |||
| Skewness | 5.05 | |||
| Kurtosis | 32.32 |
Consider Innate Pharma's intraday indicators
Innate Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Innate Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 875.38 | |||
| Daily Balance Of Power | 1.0 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 2.29 | |||
| Day Typical Price | 2.28 | |||
| Period Momentum Indicator | 0.06 | |||
| Relative Strength Index | 61.48 |
Innate Stock media impact
Far too much social signal, news, headlines, and media speculation about Innate Pharma that are available to investors today. That information is available publicly through Innate media outlets and privately through word of mouth or via Innate internal channels. However, regardless of the origin, that massive amount of Innate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Innate Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Innate Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Innate Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Innate Pharma alpha.
Innate Pharma Corporate Management
| Sonia MD | Chief VP | Profile | |
| Odile Belzunce | VP Operations | Profile | |
| Marc Bonneville | Founder | Profile | |
| Jean Fourni | Founder | Profile | |
| Henry MSc | Vice Communication | Profile | |
| DVM MBA | VP Founder | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Innate Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.